Gene signatures of activated T cells have been shown to predict response to anti-PD-1 therapy.22 In order to determine if the gene expression profile (GEP) may also predict patients capable of eliciting TR TIL products, we analysed the expression of 770 immune-related genes in 8/10 patients with FFPE-tumour RNA available. The gene discussed is PDCD1; the disease is neoplasm.